May 16, 2016 / 1:20 PM / 3 years ago

Aduro's pancreatic cancer drug fails in mid-stage study

(Reuters) - Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study.

In the study, patients were given either CRS-207 or chemotherapy or a combination of CRS-207 with Aduro’s GVAX Pancreas, the company said on Monday.

Aduro’s shares fell 33 percent to $7.14 in premarket trading.

Reporting by Ankur Banerjee in Bengaluru; Editing by Kirti Pandey

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below